ABOUT ZZOMA
Zzoma, an Alternative for CPAP

Designed by a board-certified sleep physician, The Zzoma is a positional medical device for the treatment of mild to moderate positional Obstructive Sleep Apnea (OSA), and snoring. In a multi-center clinical study, Zzoma was found to be a clinically proven effective treatment for patients with positional OSA. Your OSA treatment shouldn’t keep you awake at night. Zzoma is an affordable and comfortable alternative to CPAP therapy.

Download a Zzoma Fact Sheet Here

 Start your Journey towards Sleep Satisfaction with Zzoma!
Effective

Designed by a board certified sleep physician, Zzoma is a positioner worn around your upper torso.

Comfortable

Just as effective as CPAP therapy while allowing you to sleep comfortably on your own pillow with no mask or skin irritation.

Affordable

A single, one-time payment for Zzoma is an affordable alternative to CPAP therapy.

Zzoma Better Sleep Better Life

Better Sleep with Zzoma

Exceptional Comfort

  • Mask-free design for a natural sleep experience.
  • Gentle and unobtrusive for improved sleep quality.

Easy Adjustment

  • Easy adaptation for a smoother transition to side sleeping.
  • Simple design helps users quickly stay off their back.

More motivation

  • Improves quality of sleep for both the user and their loved ones.
  • Offers a mask-free alternative for those who find masks uncomfortable.

What patients are saying about Zzoma

Take a closer look at positional OSA

Defining positional OSA

50% of patients diagnosed with Mild OSA, 20% of Moderate OSA, and 7% of Severe OSA patients may benefit from positional therapy2

The Significance of Positional OSA

Positional OSA is a common and specific diagnosis within the spectrum of obstructive sleep apnea (OSA)3. It’s characterized by most breathing events occurring during supine sleep and can be identified via sleep studies that track body position. A substantial 47% of OSA patients may experience positional OSA exclusively.4

Challenges and Roadblocks in Positional OSA Treatment

Addressing challenges with many available therapies

Patients often struggle to consistently use PAP therapies, with non-adherence rates ranging from 29% to 83%. To improve outcomes, it’s essential to find new ways to overcome the various obstacles associated with currently available treatments. For successful treatment, CPAP non-adherence (defined as less than or equal to 4 hours of nightly use5,6 must be addressed.
PAP therapy use is highly inconsistent, with adherence rates ranging from a low of 29% to a high of 83%.

29% - 83%

An opportunity to optimize therapy

The Future of Positional OSA Therapy 

Traditional sleep therapies used for OSA are also typically used to treat positional OSA, despite the availability of less invasive, validated treatments that target positional sleep apnea. The future of positional therapy will prioritize personalized solutions, moving away from the traditional “one-size-fits-all” approach to OSA treatment.

Evolving Solutions: Zzoma's Commitment to Progress

While Zzoma positional therapy currently lacks digital feedback, Sleep Specialists LLC, the manufacturer of Zzoma, is actively developing a companion app for users. This app, along with a second-generation Zzoma device, promises to offer data-driven insights for both patients and providers.
QUESTIONS
Ask Your Doctor

Positional OSA can only be diagnosed by a sleep study and not all patients with OSA should be treated with the Zzoma. Zzoma is available by prescription only. Ask your doctor if the Zzoma Positional Device may be right for you. ​

5.0

The Zzoma device has proven to be a frontline option for many clinicians to use for sleep apnea patients in need of therapy. Our exclusive partnership allows us even more ability to grow their product line within the VA. It will mean not only a closer alignment of our two companies, but also the ability for more Veterans to be treated by therapy and still reinforce the options sleep physicians are going to have in their arsenal to treat OSA.                   
Glenn Munroe - Senior Vice President   First Nation Group

Glenn Munroe
5.0

This device has helped me to sleep with my CPAC, either on my side or my stomach and my events have gone well below the 5 threshold. Now at my next appointment in April , I’m hoping the Oximeter has better news too.

JC - Zzoma Patient

Zzoma Positional Device

5.0

I love the device and hope this email reaches all of us.
I changed the form and replaced Subject with Zzoma and filled in the default field as Zzoma Positional Device.

CM - Zzoma Patient

Awesome product

5.0

The Zzoma back pillow has gotten rid of my snoring almost completely and since It doesn't let me sleep on my back I no longer have sleep apnea. Best part I'm getting a much better sleep and my husband too. He's finally able to sleep through the night without walking me up to move to my side.
I would definately recommend your product.
Thank you Karen for your always there help.

AT - Zzoma Patient

Zzoma

5.0

Great product use it every day

MS - Zzoma Patient

Zzoma Positional Device

5.0

I love it!

YF - Zzoma Patient

Citations
1. Sleep Specialists, LLC. Patient Experience Survey. Unpublished data set; 2024 January
2. Prevalence of positional sleep apnea in patients undergoing polysomnography MJ Mador, TJ Kufel, UJ Magalang, SK Rajesh… – Chest, 2005 – Elsevier
3. Cartwright criteria, Effect of Sleep Position on Sleep Apnea Severity, R. Cartwright, 1984
4. Heinzer, R. et al, Prevalence and Characteristics of Positional Sleep Apnea in the HypnoLaus Population-based cohort, Sleep Medicine 2018; 48:157-162.
5. Sawyer, AM. et al, A systemic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions, Sleep Med Review, 2011 Dec, 15(6): 343-56
6. T. et al, Adherence to Continuous Positive Airway Pressure Therapy: the Challenge to Effective Treatment, Proceedings of the American Thoracic Society, Vol5, 2008
7. Benjafield AV et al, “Estimation of the global prevalence and burden of obstructive sleep apnea: A literature-based analysis”. Vol 7:8; 687-98. Lancet Respir Med 2019. Statistic based on US findings for adults aged 30-69.